Bacteriocins

Bacteriocins CDMO Services

From strain engineering to GMP-grade bacteriocin production for therapeutics, microbiome modulation, and food safety.

Overview

At Elise Biopharma, we offer specialized CDMO services for bacteriocins — a diverse class of ribosomally synthesized antimicrobial peptides produced by bacteria. With rising antimicrobial resistance (AMR), bacteriocins are being rediscovered as precision anti-infectives, microbiome modulators, and bio-preservatives for food and agriculture.

Unlike broad-spectrum antibiotics, bacteriocins are narrow-spectrum, potent, and often species-specific, making them ideal for applications where precision is essential. However, their clinical and industrial development is constrained by the lack of scalable manufacturing, validated QC assays, and regulatory expertise.

Elise Biopharma bridges this gap by providing end-to-end bacteriocin development and manufacturing services — from microbial strain optimization and fermentation, to purification, characterization, GMP production, and regulatory dossier support.

Whether you are developing lantibiotics for drug-resistant pathogens, engineered bacteriocins for microbiome therapeutics, or bacteriocin-based preservatives for food safety, we provide the infrastructure and expertise to accelerate your program from discovery to clinical and commercial success.

Why Bacteriocins Matter

Bacteriocins represent one of the most diverse and underexploited antimicrobial classes. They include:

• Lantibiotics (e.g., nisin, subtilin) with unique thioether rings and potent Gram-positive activity
• Colicins and microcins, narrow-spectrum peptides from E. coli with activity against Enterobacteriaceae.
• Class II bacteriocins, small heat-stable peptides widely explored for food and therapeutic use.
• Engineered hybrids, with domains swapped for tailored spectra and stability.
  

Their advantages include:

• Specificity – Minimal collateral damage to the microbiome.
• Potency – Effective at nanomolar concentrations.
• Low resistance risk – Target essential cell wall or membrane components.
• Versatility – Applications in human therapeutics, veterinary medicine, probiotics, diagnostics, and food safety.
  

The bottleneck has never been science; it has been scalability and manufacturability.

Our Bacteriocin CDMO Capabilities

1. Strain Engineering & Synthetic Biology

Bacteriocin expression begins with the right host system. Because bacteriocins are ribosomally synthesized peptides — often with unique post-translational modifications (PTMs) such as lanthionine bridges, thioether linkages, or disulfide bonds — host selection and genetic optimization are mission-critical.

At Elise Biopharma, we offer strain engineering pipelines that maximize yield, reproducibility, and scalability:

• Codon optimization and vector design – Genes encoding bacteriocins are adapted for high-yield expression in E. coli, Pichia pastoris, or alternative microbial hosts such as Bacillus subtilis or lactic acid bacteria (LAB). Optimized ribosome binding sites, rare codon usage adjustments, and secretory tags improve both translation efficiency and secretion.
• CRISPR-based metabolic rewiring – Native bacteriocin producers can be engineered to knock out competing metabolic pathways, upregulate key biosynthetic enzymes, or prevent degradation of target peptides.
• Pathway refactoring of lantibiotic biosynthetic clusters – Lantibiotics (Class I bacteriocins such as nisin) require dedicated modification enzymes (LanB, LanC). We reconstruct biosynthetic operons to improve expression balance and eliminate bottlenecks, enabling more consistent thioether crosslinking.
• Fusion constructs and leader peptide engineering – Many bacteriocins are expressed as pre-peptides requiring cleavage. Fusion tags (His-tag, SUMO, MBP) or engineered leader peptides improve folding, secretion, and simplify downstream purification.
• Promoter and expression system diversity – Tightly controlled inducible promoters (e.g., T7, arabinose, methanol-inducible AOX1 in Pichia) prevent premature toxicity in the host and allow high-density fermentation before induction.
  

2. Fermentation & Upstream Process Development

Even the best-engineered strains will fail without optimized fermentation. Bacteriocin yields are highly sensitive to oxygen tension, pH control, media composition, and induction strategy.

Elise Biopharma provides scalable upstream platforms tailored to bacteriocins:

• Bench-scale feasibility (2–10 L) – Early runs define growth kinetics, induction points, and initial titers. We perform oxygen transfer rate (OTR) studies, induction timing tests, and initial metabolic flux analysis.
• Pilot-scale fermentation (50–200 L) – Fed-batch and perfusion strategies are tested with design-of-experiment (DoE) frameworks, optimizing carbon/nitrogen ratios, trace metals, and buffering capacity. For LAB-derived bacteriocins, we adapt pH-controlled batch fermentation under microaerobic or anaerobic conditions.
• Commercial-scale GMP production (500–2,000 L) – High-cell-density fermentations using single-use or stainless-steel bioreactors, with inline pH/DO/ORP probes and real-time analytics. Controlled induction protocols minimize metabolic burden and maximize peptide yield.
• Anaerobic and stress-induced conditions – Some bacteriocins require low-oxygen environments or stress-induction triggers. We offer custom-controlled headspace aeration and low-redox fermentation conditions for these specialized workflows.
  

3. Downstream Purification

Purifying bacteriocins is challenging due to their small size, amphipathic nature, and similarity to host proteins or peptides. Elise Biopharma uses multi-step purification trains designed for efficiency, reproducibility, and regulatory compliance:

• Membrane-based ultrafiltration/diafiltration (UF/DF) – Initial concentration and buffer exchange, optimized with cut-off membranes between 1–10 kDa depending on bacteriocin size.
• Chromatography workflows –
  
  • Ion-exchange chromatography (IEX) for charge-based separation of bacteriocins from host proteins.
  • Reverse-phase chromatography (RPC) for purification of hydrophobic lantibiotics.
  • Hydrophobic interaction chromatography (HIC) to resolve amphipathic peptides.
  • Size-exclusion chromatography (SEC) for polishing and removal of aggregates.
    
• Affinity methods – For engineered bacteriocins expressed with tags or fusion domains, affinity chromatography accelerates capture and enhances recovery.
• Continuous purification platforms – Multi-column continuous chromatography reduces cost of goods (COGs) while maintaining GMP compliance.
• Endotoxin and host-cell protein removal – Multi-pass endotoxin removal methods consistently achieve <0.1 EU/mg, validated for regulatory filings.
  

4. Analytical & QC Expertise

Because bacteriocins are structurally diverse and functionally specialized, analytical methods must be equally robust. Elise Biopharma integrates state-of-the-art QC and characterization workflows:

• Structural confirmation – LC-MS/MS sequencing for identity and post-translational modification (PTM) mapping (e.g., lanthionine bridges, thioether linkages).
• Purity analysis – HPLC profiling (reverse-phase, SEC) to confirm >95% purity across batches.
• Potency assays – Standard MIC testing, time-kill curves, and bactericidal kinetics against target pathogens. For food applications, bacteriocin efficacy is validated against Listeria, Salmonella, and spoilage organisms.
• Biofilm assays – Quantifying bacteriocin-mediated biofilm inhibition for medical device coatings, food safety, and chronic infections.
• Stability profiling – Stress testing under pH extremes, elevated temperature, protease exposure, and light conditions.
• Immunogenicity assessments – Predictive in silico immunogenicity screens plus in vitro assays for cytokine release.
• ICH stability programs – Accelerated and long-term stability studies aligned with ICH Q1A(R2) requirements
  

5. Formulation Development

Formulating bacteriocins requires strategies tailored to delivery route, therapeutic target, and stability profile. Elise Biopharma provides multi-application formulation expertise:

• Injectables – Systemic bacteriocins formulated with stabilizers to prevent aggregation, with excipient libraries tested for compatibility (trehalose, arginine, mannitol).
• Oral formulations – Bacteriocins for gut microbiome modulation require enteric-coated capsules, microencapsulation, or nanoparticle embedding to protect against gastric degradation.
• Topical applications – Creams, gels, sprays, and wound dressings containing bacteriocins, tested for dermal stability, viscosity, and release kinetics.
• Food-grade preservatives – GRAS-compliant formulations stable in diverse matrices (meat, dairy, beverages), validated under FDA/EFSA frameworks.
• Encapsulation technologies – Liposomes, polymer nanoparticles, hydrogels, and PLGA microspheres used to extend half-life, enable slow release, or target specific tissues.
• Lyophilization and drying – Protocols optimized to retain bacteriocin activity upon reconstitution, critical for global shipping.

6. GMP Manufacturing & Fill-Finish

Scaling bacteriocins into GMP is where most developers stumble. Elise Biopharma offers full GMP manufacturing and aseptic fill-finish capabilities that align with regulatory requirements across therapeutics, veterinary products, and food applications.

• GMP production suites – Validated facilities for bacteriocins as therapeutic biologics, veterinary additives, or food preservatives.
• Aseptic fill-finish – Flexible formats including vials, pre-filled syringes, cartridges, and bulk packaging. Grade A isolators and validated container–closure interactions ensure sterility and potency.
• Lyophilization for global shipping – GMP lyo capabilities with accelerated and long-term stability testing.
• Supply chain & lifecycle planning – Forecasting, logistics management, cold-chain validation, and scale-up to commercial volumes.
• QP release and regulatory audits – Compliance with FDA, EMA, and USDA for human, veterinary, and food regulatory pathways.

Regulatory & Clinical Support

The regulatory environment for bacteriocins varies by application:

• Therapeutics – Treated as biologics/novel antibiotics, requiring IND/CTA filings.
• Veterinary applications – USDA, EMA, CVM frameworks.
• Food safety / bio-preservatives – GRAS (Generally Recognized As Safe) and EFSA approval pathways.
  

Elise Biopharma provides:

• CMC dossier preparation for IND/CTA submissions.
• Regulatory strategy development across human, veterinary, and food use cases.
• ISO 13485 documentation for diagnostic enzymes.
• QMS and traceability aligned with ICH Q5/Q6 and GMP.
  

Innovation & Differentiation

The bacteriocin space is still fragmented, with many programs stuck in academic labs or early biotech start-ups. What sets Elise Biopharma apart is not just capacity, but a combination of technical depth, platform versatility, and regulatory foresight that few CDMOs can offer.

• Cross-Modal Expertise – We don’t treat bacteriocins as an isolated niche. Instead, we bring experience from biologics, recombinant enzymes, probiotics, microbiome therapeutics, and AMR solutions, allowing us to apply proven bioprocessing strategies and regulatory frameworks across modalities. This cross-pollination helps clients shorten timelines and avoid reinvention.
• Proprietary Workflows for Lantibiotic Engineering – Lantibiotics such as nisin require specialized post-translational modification systems that few CDMOs understand. Elise has developed proprietary pathway-refactoring and synthetic biology workflows to ensure correct thioether bridge formation, higher yields, and more consistent bioactivity across scales.
• Advanced Analytics Beyond MICs – Traditional microbiology assays are not enough for regulatory-grade programs. We offer mechanistic potency assays, structural mapping with LC-MS/MS and NMR, biofilm inhibition studies, immunogenicity assessments, and stability stress testing, giving clients a complete CMC data package.
• Flexible & Scalable Infrastructure – From 2 L feasibility lots for proof-of-concept to 2,000 L GMP bioreactors for commercial supply, Elise provides a seamless scale-up path. We integrate digital-twin process modeling, real-time PAT analytics, and continuous purification platforms to ensure reproducibility and lower COGs.
• Global Regulatory Readiness – Bacteriocins face diverse regulatory frameworks across human therapeutics, veterinary medicine, and food applications. Elise provides end-to-end dossier support across the US (FDA, USDA), Europe (EMA, EFSA), and Asia (PMDA, NMPA), with expertise in navigating GRAS, IND, and CTA pathways.
• Integrated Innovation Mindset – Unlike traditional CDMOs that simply manufacture to spec, Elise acts as a co-development partner: exploring new formulations, co-encapsulation strategies, delivery systems, and novel regulatory routes. We help clients not only make bacteriocins, but make them better, more stable, and more clinically defensible.

Why Innovators Choose Elise Biopharma

Clients partner with Elise because we combine:

• Technical depth in microbial fermentation and peptide purification.
• Flexible infrastructure for programs from bench to commercial.
• Regulatory foresight in three verticals (human, veterinary, food).
• Speed to clinic and market, leveraging parallelized development.
• Trust — we deliver reproducibility, not just yield.
  

Whether you are developing a novel lantibiotic, a precision microbiome modulator, or a bacteriocin-based food safety agent, Elise Biopharma is the CDMO partner that can scale your vision.

Concluding remarks

Bacteriocins are not new — but their time has come. As AMR rises, microbiome therapeutics mature, and food safety becomes more urgent, bacteriocins offer a unique solution. The challenge is not science but manufacturing — and Elise Biopharma provides the bridge.

With strain engineering, fermentation, purification, QC, formulation, GMP manufacturing, and regulatory support under one roof, we accelerate bacteriocin programs from concept to commercial success.

Contact us today to discuss your bacteriocin project and explore how Elise Biopharma can help bring your innovation to market.

Email our sales team at info@elisebiopharma.com

Top 10 Bacteriocin CDMO FAQ

1. What are bacteriocins?

Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria. Unlike broad-spectrum antibiotics, they are typically narrow-spectrum and highly potent, making them ideal for precision anti-infectives, microbiome modulation, and food preservation.

2. What types of bacteriocins can Elise Biopharma manufacture?

We support multiple classes, including lantibiotics (e.g., nisin), colicins and microcins, Class II bacteriocins, and engineered hybrids with improved stability or activity.

3. Which host systems are used for bacteriocin expression?

Common hosts include E. coli, Pichia pastoris, Bacillus subtilis, and lactic acid bacteria (LAB). We also engineer native producers using CRISPR to enhance yields.

4. How scalable is bacteriocin fermentation?

Our upstream platforms run from 2 L bench-scale feasibility through 2,000 L GMP bioreactors, with fed-batch, perfusion, and anaerobic conditions available.

5. What purification strategies are used?

We use tangential-flow filtration, ion-exchange, reverse-phase, HIC, SEC, and affinity chromatography. Continuous multi-column purification reduces COGs at scale.

6. How are bacteriocins analyzed for quality?

QC includes LC-MS/MS for sequencing and PTMs, HPLC purity, MIC potency assays, biofilm inhibition studies, stability testing, and immunogenicity profiling.

7. What formulations are available?

We develop injectables, oral encapsulations, topical gels/sprays, food-grade preservatives, and lyophilized formats, with excipient libraries validated for stability and activity.

8. Do bacteriocins require special regulatory pathways?

Yes. Therapeutics follow biologics/novel antibiotic frameworks (IND/CTA), veterinary products align with USDA/EMA/CVM, and food preservatives often require GRAS/EFSA approval.

9. Can Elise provide GMP manufacturing and fill-finish?

Yes. We offer GMP production suites, aseptic fill-finish into vials, syringes, cartridges, and lyophilization, plus global supply chain and lifecycle management.

10. Why partner with Elise Biopharma for bacteriocins?

We combine synthetic biology, fermentation, purification, QC, formulation, GMP infrastructure, and regulatory support under one roof. This makes us a true end-to-end CDMO partner for bacteriocins in human, veterinary, and food applications.

Need help with your next Bacteriocin project?

Email our team at info@elisebiopharma.com